Proteins are frequently modified by complex carbohydrates (glycans) that play central roles
in maintaining the structural and functional integrity of cells and tissues in humans and lower …

Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

Anti‐drug antibody formation following factor VIII (FVIII) replacement therapy is the most
important treatment‐related complication in patients with severe haemophilia A. A significant …

Dendritic cells (DCs) are mediators between innate and adaptive immunity and vital in
initiating and modulating antigen-specific immune responses. The most important site for …

Background Several studies have suggested Black and Hispanic hemophilia A (HA) patients
in the United States suffer higher incidences of neutralizing anti-FVIII antibodies (inhibitors) …

The development of neutralizing anti-FVIII antibodies (inhibitors) is a major complication of
FVIII protein replacement therapy in patients with hemophilia A (HA). Although multiple lines …

Introduction: Anti-drug antibody (ADA) responses are becoming an increasing concern as
more highly engineered and sophisticated biotherapeutics enter the clinic. An arsenal of …

Adeno-associated virus (AAV) vectors have been successfully applied in hemophilia clinical
trials. However, this approach is limited to patients without AAV-neutralizing antibodies …

Discoidin (DS) domains are found in eukaryotic and prokaryotic extracellular and
transmembrane multidomain proteins. These small domains play different functional roles …

Hemophilia A is a bleeding disorder characterized by the absence or dysfunction of blood
coagulation factor VIII (FVIII). Patients are treated with regular infusions of FVIII concentrate …